Insider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 26,250 Shares of Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 26,250 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $1,575,000.00. Following the transaction, the insider now owns 144,601 shares in the company, valued at $8,676,060. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Neurocrine Biosciences, Inc. (NBIX) traded up 0.02% during midday trading on Friday, hitting $57.74. The stock had a trading volume of 1,086,081 shares. The stock’s market cap is $5.09 billion. Neurocrine Biosciences, Inc. has a 12-month low of $37.35 and a 12-month high of $60.00. The company’s 50-day moving average price is $52.41 and its 200 day moving average price is $48.37.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.01. The business had revenue of $6.34 million during the quarter, compared to the consensus estimate of $0.61 million. During the same period in the prior year, the company earned ($0.46) earnings per share. On average, equities research analysts predict that Neurocrine Biosciences, Inc. will post ($2.45) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/08/insider-selling-neurocrine-biosciences-inc-nbix-insider-sells-26250-shares-of-stock.html.
Several equities analysts recently weighed in on NBIX shares. ValuEngine upgraded Neurocrine Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Jefferies Group LLC restated a “buy” rating and set a $67.00 price target on shares of Neurocrine Biosciences in a research note on Monday, May 22nd. BidaskClub upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. BMO Capital Markets upped their price target on Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a research note on Friday, August 4th. Finally, Piper Jaffray Companies set a $68.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Thursday, August 24th. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Neurocrine Biosciences currently has a consensus rating of “Buy” and a consensus price target of $68.25.
Several large investors have recently made changes to their positions in the business. Janus Henderson Group PLC bought a new position in shares of Neurocrine Biosciences in the second quarter worth about $246,888,000. BlackRock Inc. increased its stake in shares of Neurocrine Biosciences by 14,216.0% in the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock worth $217,884,000 after purchasing an additional 4,996,784 shares during the period. Wellington Management Group LLP increased its stake in shares of Neurocrine Biosciences by 554.4% in the first quarter. Wellington Management Group LLP now owns 2,407,376 shares of the company’s stock worth $104,240,000 after purchasing an additional 2,039,509 shares during the period. Janus Capital Management LLC increased its stake in shares of Neurocrine Biosciences by 85.0% in the first quarter. Janus Capital Management LLC now owns 4,359,384 shares of the company’s stock worth $188,759,000 after purchasing an additional 2,002,899 shares during the period. Finally, TimesSquare Capital Management LLC increased its stake in shares of Neurocrine Biosciences by 299.4% in the second quarter. TimesSquare Capital Management LLC now owns 2,315,373 shares of the company’s stock worth $106,507,000 after purchasing an additional 1,735,700 shares during the period.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.